In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related

  • Yanhua Bai
  • Ting Guo
  • Xiaozheng Huang
  • Qi Wu
  • Dongfeng Niu
  • Xinqiang Ji
  • Qin Feng
  • Zhongwu Li
  • Kennichi Kakudo
Original Article

Abstract

Immune checkpoint inhibitor therapies targeting PD-L1/PD-1 have been shown to be effective in treating several types of human cancer. In papillary thyroid carcinoma (PTC), little is known about the expression of PD-L1/PD-1 in the tumor microenvironment or its potential correlation with BRAF V600E mutation status. In this study, we examined the expression of PD-L1, PD-1, and BRAF V600E in PTC by immunohistochemistry and investigated the clinical significance of expression status. We studied the expression of PD-L1, PD-1, and BRAF V600E by immunohistochemical staining in 110 cases of PTC with a diameter > 1 cm. Cases with a background of chronic lymphocytic thyroiditis (CLT) were excluded, as differentiating lymphocytes in the context of CLT from tumor-infiltrating lymphocytes (TILs) is difficult. We classified PD-L1+/PD-1+ expression as type 1 (41%), PD-L1−/PD-1− as type 2 (17%), PD-L1+/PD-1− as type 3 (5%), and PD-L1−/PD-1+ as type 4 (37%). Significant correlations were found between expression of BRAF V600E and that of PD-L1 and PD-1. The positive correlation observed between expression of BRAF V600E and PD-L1/PD-1 suggests that immunotherapies targeting PD-L1/PD-1 might be effective for PTC patients with the BRAF V600E mutation, which are refractory to radioiodine therapy.

Keywords

BRAF V600E PD-L1 PD-1 Papillary thyroid carcinoma Immunohistochemistry 

Notes

Author contributions

BY, GT, KK, and LZ conceived and designed the experiments. HX and WQ performed the experiments. BY and ND reviewed the slides; JX and FQ analyzed the data. BY and GT wrote the manuscript.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bai Y, Kakudo K, Li Y, Liu Z, Ozaki T, Ito Y, Kihara M, Miyauchi A (2008) Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci 99:1908–1915PubMedGoogle Scholar
  2. 2.
    Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J (1985) Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55:805–828CrossRefPubMedGoogle Scholar
  3. 3.
    Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245–262CrossRefPubMedGoogle Scholar
  4. 4.
    Baquero P, Sanchez-Hernandez I, Jimenez-Mora E, Orgaz JL, Jimenez B, Chiloeches A (2013) (V600E) BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism. Cancer Lett 335:232–241CrossRefPubMedGoogle Scholar
  5. 5.
    Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457PubMedGoogle Scholar
  6. 6.
    Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274CrossRefPubMedGoogle Scholar
  7. 7.
    Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293–12297CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800CrossRefPubMedGoogle Scholar
  9. 9.
    Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ilie M, Hofman V, Dietel M, Soria JC, Hofman P (2016) Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 468:511–525CrossRefPubMedGoogle Scholar
  12. 12.
    Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G (2015) PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev 41:114–121CrossRefPubMedGoogle Scholar
  13. 13.
    Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19:1021–1034CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, Ma W, Zhang B, Han W, Xia J, Chen H, Zhang Y (2016) The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget 7:73068–73079PubMedPubMedCentralGoogle Scholar
  15. 15.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75:2139–2145CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tang H, Qiao J, Fu YX (2016) Immunotherapy and tumor microenvironment. Cancer Lett 370:85–90CrossRefPubMedGoogle Scholar
  18. 18.
    Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885–4893CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184–199CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG (2016) Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget 31:32318–32328Google Scholar
  21. 21.
    Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL, Chung JH (2017) Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 24:97–106CrossRefPubMedGoogle Scholar
  22. 22.
    Cunha LL, Marcello MA, Morari EC, Nonogaki S, Conte FF, Gerhard R, Soares FA, Vassallo J, Ward LS (2013) Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr Relat Cancer 20:103–110CrossRefPubMedGoogle Scholar
  23. 23.
    Wu H, Sun Y, Ye H, Yang S, Lee SL, de las Morenas A (2015) Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets. Pathol Oncol Res 21:695–701CrossRefPubMedGoogle Scholar
  24. 24.
    Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC Jr, Haugen BR, French JD (2016) Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 101:2863–2873CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A (2014) Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 20:3446–3457CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, Amin S, Freeman GJ, Parangi S (2016) Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget 7:17194–17211CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zuo H, Tang W, Yasuoka H, Nakamura Y, Ito Y, Miyauchi A, Kakudo K (2007) A review of 227 cases of small papillary thyroid carcinoma. Eur J Surg Oncol 33:370–375CrossRefPubMedGoogle Scholar
  28. 28.
    Bai Y, Zhou G, Nakamura M, Ozaki T, Mori I, Taniguchi E, Miyauchi A, Ito Y, Kakudo K (2009) Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol 22:887–894CrossRefPubMedGoogle Scholar
  29. 29.
    Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, Liang Z (2015) Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Int J Clin Exp Pathol 8:15072–15078PubMedPubMedCentralGoogle Scholar
  30. 30.
    Pyo JS, Sohn JH, Kang G (2015) BRAF immunohistochemistry using clone VE1 is strongly concordant with BRAF (V600E) mutation test in papillary thyroid carcinoma. Endocr Pathol 26:211–217CrossRefPubMedGoogle Scholar
  31. 31.
    Liu H, Li Z, Wang Y, Feng Q, Si L, Cui C, Guo J, Xue W (2014) Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1. Pathol Int 64:601–606PubMedGoogle Scholar
  32. 32.
    Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M (2012) Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36:844–850CrossRefPubMedGoogle Scholar
  33. 33.
    Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng G, Zhou L, Jia L, Huang X, Kang Q, Lin D, Gao J, Shen L (2016) PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol 55:182–189CrossRefPubMedGoogle Scholar
  34. 34.
    Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou V, Hauben E, Rolfo C, Rottey S, Pauwels P (2017) CD70 and PD-L1 in anaplastic thyroid cancer-promising targets for immunotherapy. Histopathology 71:357–365CrossRefPubMedGoogle Scholar
  35. 35.
    Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C, Bible KC (2017) Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab 102:1943–1950CrossRefPubMedGoogle Scholar
  36. 36.
    Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL (2014) BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 24:1385–1393CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJ (2016) Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res 76:6964–6974CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yanhua Bai
    • 1
  • Ting Guo
    • 2
  • Xiaozheng Huang
    • 1
  • Qi Wu
    • 1
  • Dongfeng Niu
    • 1
  • Xinqiang Ji
    • 3
  • Qin Feng
    • 1
  • Zhongwu Li
    • 1
  • Kennichi Kakudo
    • 4
  1. 1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of PathologyPeking University Cancer Hospital & InstituteBeijingChina
  2. 2.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Division of Gastrointestinal Cancer Translational Research LaboratoryPeking University Cancer Hospital & InstituteBeijingChina
  3. 3.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical StatisticsPeking University Cancer Hospital & InstituteBeijingChina
  4. 4.Department of Pathology, Nara HospitalKindai University Faculty of MedicineIkomaJapan

Personalised recommendations